PRKDC

Across TCGA pan-cancer cohorts, PRKDC RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated PRKDC data layer compared with 11 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher PRKDC RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PRKDC expression acts as an unfavorable survival marker, although some lineages such as UCS and KIRC show a favorable association.

MESO, UVM, and ACC are the cancer types where PRKDC RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.268	0.481	<.001	108	view →
UVM	DFS	Quartile	All	0.250	0.756	<.001	102	view →
ACC	DFS	Tertile	All	0.368	0.812	<.001	93	view →
UCS	OS	Median	III,IV	0.620	0.291	.012	66	view →
UCEC	DFS	Tertile	All	0.774	0.920	<.001	40	view →
LIHC	OS	Tertile	All	0.657	0.831	.002	40	view →
SARC	OS	Tertile	All	0.428	0.815	<.001	34	view →
BLCA	DFS	Quartile	All	0.409	0.579	.001	33	view →
KICH	DFS	Median	II,III,IV	0.556	0.922	.003	31	view →
CESC	OS	Tertile	All	0.835	0.943	.004	28	view →
LGG	OS	Median	All	0.745	0.881	<.001	27	view →
KIRP	DFS	Tertile	All	0.868	0.964	.002	27	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

PRKDC–MESO (OS)

Open the MESO breakdown →